Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
UBS
QuintilesIMS
Colorcon
US Department of Justice
Boehringer Ingelheim

Generated: May 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,677,326

« Back to Dashboard

Which drugs does patent 6,677,326 protect, and when does it expire?

Patent 6,677,326 protects RAYOS and is included in one NDA.

This patent has fifteen patent family members in seven countries.

Summary for Patent: 6,677,326
Title: Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
Abstract:The subject invention concerns a unit dose formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid. One embodiment of a method of the invention concerns once daily administration of the unit dose formulation between midnight and 6 a.m. for the treatment of rheumatoid arthritis.
Inventor(s): Bardsley; Hazel Judith (Cambridge, GB), Bannister; Robin Mark (Essex, GB), Gilbert; Julian Clive (Essex, GB)
Assignee: Arakis, Ltd. (GB)
Application Number:10/263,044
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,677,326
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,677,326
Patent Claim Types:
see list of patent claims
Formulation; Use; Dosage form;

Drugs Protected by US Patent 6,677,326

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Horizon Pharma Usa RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 AB RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE ➤ Sign Up
Horizon Pharma Usa RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 AB RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,677,326

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9905898Mar 15, 1999
United Kingdom0023220Sep 21, 2000

International Family Members for US Patent 6,677,326

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 3179000 ➤ Sign Up
Australia 771088 ➤ Sign Up
Australia 8789501 ➤ Sign Up
Canada 2361503 ➤ Sign Up
Canada 2422991 ➤ Sign Up
European Patent Office 1158988 ➤ Sign Up
European Patent Office 1318816 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Argus Health
AstraZeneca
Cantor Fitzgerald
Deloitte
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.